Skip to main content
SpringerLink
Log in

Anti-convulsant Agents: Sulthiame

  • Reference work entry
  • First Online:
NeuroPsychopharmacotherapy

  • 159 Accesses

Abstract

Sulthiame (STM) is an antiepileptic drug with a small carbonic anhydrase inhibition effect. Its half-life is about 8.65 h. There are relevant interactions with carbamazepine, phenobarbital, primidone, phenytoin, and clobazam. It has been shown to be effective in benign childhood epilepsy with centrotemporal spikes and West syndrome and may be useful in other epilepsy syndromes like myoclonic epilepsies and Rett syndrome as well. The most common side effects are hyperventilation and paresthesia. Very rarely life-threatening adverse events like Stevens-Johnson syndrome and DRESS may occur.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 949.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 1,399.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Ahrend KF, Nagy L, Tiess D. Zur Morphologie und Analytik der Sultiamum-Intoxikation. Arch Toxikol. 1969;24:229–37.

    Article  CAS  PubMed  Google Scholar 

  • Aviram A, Czaczkes JW, Rosenmann E. Acute renal failure associated with sulthiame. Lancet. 1965;7389:818.

    Article  Google Scholar 

  • Basnec A, Skarpa D, Barisic N, Jurin M, Mucic-Pucic B. Rizik Javljanja drugog napadaja u nelijecene djece s benignom parcijalnom epilepsijom s centrotemporalnim siljcima – prospektivno istrazivanje. Acta Med Croatica. 2005;59:59–62.

    PubMed  Google Scholar 

  • Borggraefe I, Bonfert M, Bast T, Neubauer BA, Schotten KJ, Maymann K, et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood. A double-blinded, randomized, controlled trial (German HEAD study). Eur J Paediatr Neurol. 2013;17:507–14.

    Article  PubMed  Google Scholar 

  • Bray CA, Bower BD. Ospolot in epilepsy. Dev Med Child Neurol. 1963;5:409–11.

    Article  CAS  PubMed  Google Scholar 

  • Bresnahan R, Martin-McGill KJ, Milburn-McNulty P, Powell G, Sills GJ, Marson AG. Sulthiame add-on therapy for epilepsy. Cochrane Database Syst Rev. 2019;(8):CD009472. https://doi.org/10.1002/14651858.CD009472.pub4.

  • Claassen C, Wirrell EC. Sulthiame. In: Panayiotopoulos CP, editor. Atlas of epilepsies. London: Springer Verlag London; 2010. p. 1837–41. https://doi.org/10.1007/987-1-84882-128-6_281.

    Chapter  Google Scholar 

  • Dao K, Thoueille P, Decosterd LA, Mercier T, Guidi M, Bardinet C, et al. Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: a pilot study in healthy volunteers. Pharmacol Rs Perspect. 2020;8:e00558.

    CAS  Google Scholar 

  • Debus OM, Kurlemann G. Sulthiame in the primary therapy of West syndrome: a randomized double-blind placebo-controlled add-on trial on baseline Pyridoxine medication. Epilepsia. 2004;45:103–8.

    Article  CAS  PubMed  Google Scholar 

  • Doose H, Kluge D, Ehmsen U. Erfahrungen mit Ospolot bei der Behandlung kindlicher Epilepsien. Med Klin. 1964;59:271–4.

    CAS  PubMed  Google Scholar 

  • Egli M, Hess R, Wad M. Therapeutische Serumkonzentrationen von Sulthiam. Nervenarzt. 1978;49:401–4.

    Google Scholar 

  • Engelmeier MP. Über die klinische Erprobung antiepileptischer Medikamente unter besonderer Berücksichtigung des Ospolots. Dtsch Med Wochenschr. 1960;85:2207–11.

    Article  CAS  PubMed  Google Scholar 

  • Fachinformation Ospolot, Desitin 2019.

    Google Scholar 

  • Fong CY, Hashim N, Gan CS, Chow TK, Tay CG. Sulthiame-induced drug reaction with eosinophilia and systemic symtoms (DRESS). Eur J Paediatr Neurol. 2016;20:957–61.

    Article  PubMed  Google Scholar 

  • Green JR, Troupin AS, Halpern LM, Friel P, Kanarek P. Sulthiame: evaluation as an anticonvulsant. Epilepsia. 1974;15:329–49.

    Article  CAS  PubMed  Google Scholar 

  • Hansen JM, Kristensen M, Skovsted L. Sulthiame (Ospolot) an inhibitor of diphenylhydantoin metabolism. Epilepsia. 1968;9:17–22.

    Article  CAS  PubMed  Google Scholar 

  • Huppke P, Kohler K, Brockman K, Stettner GM, Gartner J. Treatment of epilepsy in Rett syndrome. Eur J Paediatr Neurol. 2007;11:10–6.

    Article  PubMed  Google Scholar 

  • Ingram TT, Ratcliffe SG. Clinical trial of Ospolot in epilepsy. Dev Med Child Neurol. 1963;5:313–5.

    CAS  PubMed  Google Scholar 

  • Koepp MJ, Patsalos PN, Sander JWAS. Sulthiame in adults with refractory epilepsy and learning disability: an open trial. Epilepsy Res. 2002;50:277–82.

    Article  CAS  PubMed  Google Scholar 

  • Leniger T, Wiemann M, Bingmann D, Widman G, Hufnagel A, Bonnet U. Carbonic anhydrase inhibitor sulthiame reduces intracellular ph and epileptiform activity of hippocampal CA3 neurons. Epilepsia. 2002;43:469–74.

    Article  CAS  PubMed  Google Scholar 

  • Lerman P, Nussbaum E. The use of sulthiame in myoclonic epilepsy of childhood and adolescence. Acta Neurol Scand Suppl. 1975;60:7–12.

    Article  CAS  PubMed  Google Scholar 

  • Li JM, Li ZH, Jing YQ, Pan DM, Xu P, Hu D, et al. A randomized controlled multicentre clinical study on sulthiame in the treatment of GTCS. J Clin Neurol. 2000;13:345–7.

    Google Scholar 

  • Liu MC. Clinical experience with sulthiame (Ospolot) Br J Psychiat. 1966;112:621–28.

    Google Scholar 

  • May TW, Korn-Merker E, Rambeck B, Boenigk HE. Pharmacokinetics of sulthiame in epileptic patients. Ther Drug Monit. 1994;16:251–7.

    Article  CAS  PubMed  Google Scholar 

  • May TW, Rambeck B, Jürgens U. Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comediaction. Ther Drg Monit. 2002;24:366–74.

    Article  CAS  Google Scholar 

  • Milburn-McNulty P, Powell G, Sills GJ, Marson AG. Sulthiame monotherapy for epilepsy. Cochrane Database Syst Rev. 2014;(3):CD010062. https://doi.org/10.1002/14651858.CD10062.pub2.

  • Moffatt WR, Siddiqui AR, MacKay DN. The use of sulthiame with disturbed mentally subnormal patients. Br J Psychiatry. 1970;117:673–8.

    Article  CAS  PubMed  Google Scholar 

  • Mykyta LJ. A case of sulthiame overdose. Med J Aust. 1968;2:118–9.

    Article  CAS  PubMed  Google Scholar 

  • Rabe F, Penin H, Mathes A. Erfahrungen mit Ospolot in der Epilepsiebehandlung. Dtsch Med Wochenschr. 1962;87:953–9.

    Article  CAS  PubMed  Google Scholar 

  • Rating D, Wolf C, Bast T. Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Epilepsia. 2000;41:1284–8.

    Article  CAS  PubMed  Google Scholar 

  • Siniatchin M, Groppa S, Siebner H, Stephani U. A single dose of sulthiame induces a selective increase in resting motor threshold in human motor cortex: a transcranial magnetic stimulation study. Epilepsy Res. 2006;72:18–24.

    Article  Google Scholar 

  • Taafe A, O’Brien C. A case of Stevens-Johnson syndrome associated with the anticonvulsants sulthiame and ethosuximide. Br Dent J. 1975;138:172–4.

    Article  Google Scholar 

  • Wirth W, Hoffmeister F, Friebel H, Sommer S. Zur Pharmakologie des N-(4´-Sulfamylphenyl)-butansultam-(1,4). Dtsch Med Wochenschr. 1960;85:2195–9.

    Article  CAS  PubMed  Google Scholar 

  • Yamamoto Y, Takahashi Y, Imai K, Mogami Y, Matsusa K, Nakai M, et al. Interaction between sulthiame and clobazam, sulthiame inhibits the metabolism of clobazam, possibly via action on CYP2C19. Epilepsy Behav. 2014;34:124–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Neurologie, Universitätsmedizin Rostock, Rostock, Germany

    Johannes Rösche

  2. Hephata Klinik, Schwalmstadt, Germany

    Johannes Rösche

Authors
  1. Johannes Rösche
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy, University Hospital Wuerzburg, Wuerzburg, Germany

    Peter Riederer

  2. Institute of Psychological Medicine (IPM), Soyen, Germany

    Gerd Laux

  3. Centre for Research Promotion and Support, Fujita Health University, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Würzburg, Germany

    Christian Riederer

Section Editor information

  1. Beta Neurology – Competence Center for Epilepsy, Beta Klinik GmbH, Bonn, Germany

    Christian E. Elger FRCP

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Rösche, J. (2022). Anti-convulsant Agents: Sulthiame. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-030-62059-2_307

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-62059-2_307

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-62058-5

  • Online ISBN: 978-3-030-62059-2

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation